Wire · opportunities
FDA Expands Hyrnuo Use in HER2-Mutated Lung Cancer
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 11 September 2026 · Fusion42 review
The FDA expanded approval for Bayer’s Hyrnuo to treat first-line HER2-mutated non-small cell lung cancer, following positive trial results. This places Bayer in stronger competition with other HER2 drugs like Boehringer Ingelheim’s Hernexeos and broadens treatment options for this rare cancer subtype.
This Wire brief sits within Fusion42's coverage of Biotech, and 5 sources have reported it between 9 Sep 2026 and 14 Sep 2026.
◆ ◆ The Wire takeaway
Your HER2-targeted lung cancer drug just faced its first major competitor in first-line use. This approval creates urgency to either accelerate clinical confirmation or differentiate by outcomes to keep early treatment market share.
◆ Coverage
5 sources · first reported 9 Sep 2026 · latest 14 Sep 2026
◆ Related on Wire
◆ Topics